The goal of this randomized controlled double-blind clinical trial is to test the drug
tecovirimat in patients with mpox (previously known as monkeypox) disease.
The main questions it aims to answer are:
- Is tecovirimat effective in treating mpox infection.
- Is tecovirimat safe to treat patients with mpox infection.
Participants will receive either the drug tecovirimat orally, 600 mg twice per day, or a
matching placebo. The outcome of the infection and the side effect experienced will be
compared between the two groups.
Phase:
Phase 4
Details
Lead Sponsor:
Miquel Ekkelenkamp
Collaborators:
Erasmus Medical Center European Clinical Research Alliance for Infectious Diseases (ECRAID) Universiteit Antwerpen